about
Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastomaEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesAntagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIMGenetic risk factors in typical haemolytic uraemic syndrome.IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastomaEffect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2).A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition.Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases.High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastomaMajor histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer.T and NK cells: two sides of tumor immunoevasionThe putative role of endoplasmic reticulum aminopeptidases in autoimmunity: insights from genomic-wide association studies.Endoplasmic reticulum aminopeptidase 1 function and its pathogenic role in regulating innate and adaptive immunity in cancer and major histocompatibility complex class I-associated autoimmune diseases.Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors.MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors.The Role of HCMV and HIV-1 MicroRNAs: Processing, and Mechanisms of Action during Viral Infection.NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues.Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum.The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress.Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes.Exploring myelin basic protein for HLA class I-binding sequences.Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains.Unfolded HLA class I alpha chains and their use in an assay of HLA class-I-peptide binding.HLA class I binding of synthetic nonamer peptides carrying major anchor residue motifs of HLA-B27 (B*2705)-binding peptides.ERAAP modulation: A possible novel strategy for cancer immunotherapy?Control of cross-presentation during dendritic cell maturation.Assembly and selective "in synthesis" labeling of quenched fluorogenic protease substrates.Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum.N-linked glycosylation selectively regulates the generic folding of HLA-Cw1.PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.Global changes in gene expression in Escherichia coli K12 induced by bacteriophage Mu Gem protein.Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian familiesAngiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypesHedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinomaExpression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy
P50
Q26822652-7D15D733-F52F-4CFE-8DB5-44CC8C1F5FF9Q26999187-92B3A290-17B2-4F7B-9322-9CC86195D650Q33336561-AC7A602C-8085-49D1-909E-D335D4C78A6DQ33382580-0EA268EF-D146-4670-92CA-A9A148D21D92Q34447613-7050ED1B-F0C1-4EDE-A6EB-3EE3448F982CQ34479328-3F521B1F-BAB9-4B83-8B0C-5AC8AFC56FA2Q34741321-5D942C11-EDFE-4739-9AAA-AA4AC8DBF87EQ34801827-A3E3EAA6-550E-4153-A79C-FDD26D5D5A54Q35036462-0464D10C-70FB-4C86-A630-FE9FE5E037BCQ35703570-988F3C6A-49A6-4003-A07C-89E101667392Q36197201-58B28DA8-568E-4C9F-9F93-2B811FEA30EAQ36753355-28CF0C24-131B-4388-82D5-60E42168BAF9Q38009114-E23093D8-1E62-43B2-B178-A320B6C0A651Q38234401-5C21BD2F-0399-4407-A977-71BD0D4D2B38Q38676393-1C1EEF42-5531-457F-B435-F766FBB7039EQ38697986-2F37CCEA-F670-467F-9665-2E8E621F8BF0Q38919570-ED2BE742-48B7-4A92-9D99-BC347BD63134Q39292502-F03EFD75-7CEC-4DFF-BFB0-37DBFB54F7F0Q39747586-F0B24126-6B28-4834-8976-D4FB7B0DF11DQ39876473-A0A3E078-4B59-459C-9734-FA58B9173C80Q39994617-EE5A9EF2-1563-44F7-AE03-CAACBC96E431Q40778984-57E06603-4844-4BDF-B90A-C1642B8AA2A6Q40842264-1445529B-9F24-4B53-8603-7D7A337B9EF4Q41316816-C91B77E8-60CB-41EA-9AA1-C1EEBA8204E8Q41400750-A9ACF40A-129A-45CA-8065-9B451694EEF5Q41447050-507B3504-C13F-4098-80DC-A518B781B8C7Q41518526-3AAA8020-A5C6-4E66-AE05-5F6362553C99Q41574554-BC0E9F18-881D-4EAE-8FA1-49BD1803C17FQ41580136-0A38C2A4-0D9B-4AB4-9799-2E6ACC1AA900Q42204292-70284F9A-40ED-4C24-B00B-DD81B5AE0F9EQ44759317-5FF3FEF6-E7F8-4756-9558-816E273BEC1EQ45164248-6B5F6357-2A34-4288-8868-B184AD1C6BFCQ46503099-26183F1E-0C3C-48C8-86D2-8E5E42D91885Q52586447-713A4534-B085-457F-BB65-7C8C248839EDQ53456124-36BAA0E3-89C8-4211-964F-C27066229839Q54703455-2644E366-F699-421A-B51E-5FE7171C9690Q56907091-34044539-FC1F-4F32-8ADF-5C94471A5741Q58620517-F9AB2499-1905-47C2-8F24-162B5D76E9A4Q60222808-F1299B57-F895-4D93-9A3E-82982984311CQ60439830-6DFECB85-60D5-446E-BF5B-4B2B4303C650
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Doriana Fruci
@ast
Doriana Fruci
@en
Doriana Fruci
@es
Doriana Fruci
@nl
Doriana Fruci
@sl
type
label
Doriana Fruci
@ast
Doriana Fruci
@en
Doriana Fruci
@es
Doriana Fruci
@nl
Doriana Fruci
@sl
prefLabel
Doriana Fruci
@ast
Doriana Fruci
@en
Doriana Fruci
@es
Doriana Fruci
@nl
Doriana Fruci
@sl
P106
P1153
6603090976
P21
P2798
P31
P496
0000-0003-3388-7296